Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 7/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13672549 | 1.00 | MAPK14 (0.42) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL13672578 | 1.00 | MAPK14 (0.42) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL4485397 | 0.91 | MAPK14 (0.40) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL13672546 | 0.87 | MAPK14 (0.43) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL4482831 | 0.87 | MAPK14 (0.39) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL13672575 | 0.87 | MAPK14 (0.39) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL4485865 | 0.86 | MAPK14 (0.49) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL4484185 | 0.85 | MAPK14 (0.45) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL4754922 | 0.84 | MAPK14 (0.39) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL4754927 | 0.83 | MAPK14 (0.39) | MAPK14MAPK8MAPK11MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608603-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| EP-1919914-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20070049597-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| WO-2007023115-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049597-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAPK9, MAPK3 | MAPK14 22/4885MAPK8 5/4885MAPK11 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.